Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) replication (EV71/CVA16 replication)

Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are the primary causative agents of Hand, Foot, and Mouth Disease (HFMD), a common infectious disease in children (Source: NIH, 2023). The replication process of these viruses involves several critical steps, including viral entry, polyprotein processing by viral proteases (2A and 3C), and genome replication by the RNA-dependent RNA polymerase (3Dpol) (Source: PubMed, 2021). While 'replication' is a biological process rather than a single molecular target, it is the focus of antiviral drug development aimed at reducing viral load and preventing severe neurological complications (Source: Nature Communications, 2020). Drugs such as Rupintrivir target the 3C protease to inhibit polyprotein cleavage, while others like Ribavirin interfere with the polymerase activity (Source: Journal of Virology, 2019). Targeting the replication cycle is essential for managing outbreaks and treating patients at risk of systemic disease (Source: StatPearls, 2023). Understanding the nuances of EV71 and CVA16 replication is vital for developing broad-spectrum antivirals that can mitigate the risk of brainstem encephalitis and pulmonary edema (Source: Antiviral Research, 2022). This process serves as a critical functional endpoint for evaluating the efficacy of novel therapeutic candidates in both in vitro and in vivo models (Source: PubMed, 2021).

Other names

HFMD viral replicationEV-A71 and CV-A16 replication cycleEnterovirus replication

Inhibition of viral 3C protease, inhibition of RNA-dependent RNA polymerase (3Dpol), or prevention of viral uncoating by binding to the capsid pocket (Source: PubMed, 2021).